Journal of Medicinal Chemistry p. 5414 - 5433 (2019)
Update date:2022-08-15
Topics:
Guo, Zuhao
Zhang, Zhuqing
Yang, Hong
Cao, Danyan
Xu, Xiaowei
Zheng, Xingling
Chen, Danqi
Wang, Qi
Li, Yanlian
Li, Jian
Du, Zhiyan
Wang, Xin
Chen, Lin
Ding, Jian
Shen, Jingkang
Geng, Meiyu
Huang, Xun
Xiong, Bing
PRMT4 is a type I protein arginine methyltransferase and plays important roles in various cellular processes. Overexpression of PRMT4 has been found to be involved in several types of cancers. Selective and in vivo effective PRMT4 inhibitors are needed for demonstrating PRMT4 as a promising therapeutic target. On the basis of compound 6, a weak dual PRMT4/6 inhibitor, we constructed a tetrahydroisoquinoline scaffold through a cut-and-sew scaffold hopping strategy. The subsequent SAR optimization efforts employed structure-based approach led to the identification of a novel PRMT4 inhibitor 49. Compound 49 exhibited prominently high potency and selectivity, moderate pharmacokinetic profiles, and good antitumor efficacy in acute myeloid leukemia xenograft model via oral administration, thus demonstrating this compound as a useful pharmacological tool for further target validation and drug development in cancer therapy.
View MoreContact:0572-2722882
Address:1201,F3,xinghuibandao,
Taixing Shenfeng Chemical Co., Ltd.
Contact:+86-523-87117033, 87117666
Address:4# Yinsanlu, Huangqiao town, Taixing, Jiangsu, China.
Nanjing Legend Pharmaceutical & Chemical Co., Ltd.
Contact:+86-25-83767696
Address:14-7 Zhongshan Lu Guluo District, Nanjing
MedicalChem(Yancheng)Manuf.Co.,Ltd.
Contact:+86-515-84383366
Address:Touzeng BinHai, YanCheng City, JiangSu Province, China
JinTan Pingsheng Chemical Co.,Ltd
Contact:+86-519-82828200
Address:NO.11Danfengxilu Road,Jintan City,Jiangsu,China
Doi:10.1021/ja01618a080
(1955)Doi:10.1007/s11696-020-01363-3
(2021)Doi:10.1248/cpb.45.715
(1997)Doi:10.1021/om970044p
(1997)Doi:10.1080/07328319708001351
(1997)Doi:10.1021/jo9703818
(1997)